详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Jihui Hao[1] * ; Li Zheng[2] ; Dai Ruihong[3] ; Ying Jieer[4] ; Qi Xu[5] ; Li-Wei Wang[6] ; Yongdong Jin[7]

; Ying Zhao[8] ; Yueyin Pan[9] ; Lulu Liu[10] ; Jun Zhang[11] ; Yuping Sun[12] ; Zuoxing Niu[12] ; Jun Yao[13] ; Dong Hua[14] ; Mingjun Zhang[15] ; Dai Guanghai[16] ; Yulong Zhang[17] ; Hui Zhou[17] ; Feng Bi[18] ;

机构： [1]Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China [2]GCP center, West China Hospital, Sichuan University, Chengdu, China [3]Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China [4]Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China [5]Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China [6]Oncology Department, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China [7]Department of Abdominal Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliate Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China [8]Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China [9]Department of Oncology, Anhui Provincial Hospital, Hefei, China [10]Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [11]Oncology Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [12]Shandong Cancer Hospital, Jinan, China [13]The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China [14]Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China [15]The Second Hospital of Anhui Medical University, Hefei, China [16]Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China [17]Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China [18]Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

出处：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study

文献详情